Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- METAvivor
- Breast Cancer Research Foundation
- Susan G. Komen
- Italian Association for Cancer Research
This publication has 20 references indexed in Scilit:
- The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of DevelopmentCancer Discovery, 2024
- Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United KingdomBritish Journal of Cancer, 2024
- Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2023
- Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerNature Communications, 2023
- Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyAnnals of Oncology, 2022
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerAnnals of Oncology, 2021
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateJournal of Clinical Oncology, 2020
- Genetic determinants of the molecular portraits of epithelial cancersNature Communications, 2019
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast CancerJournal of Clinical Oncology, 2018
- Real-World Evidence — What Is It and What Can It Tell Us?New England Journal of Medicine, 2016